TriSalus Life Sciences Inc (TLSI) — Titan Protect Analysis

TLSI

TriSalus Life Sciences Inc

Healthcare · ·

$3.17

Data: 2026-06-03

✓ ETHICAL PASS

NONE MOAT

LIMITED

Data Confidence: 0.0%

Key Metrics

How this company measures up on the fundamentals that matter

Market Cap

$198M

Total market value of the company

Trailing P/E

N/A

Forward P/E

-12.92

Based on estimated future earnings — lower means cheaper

Rev Growth

-2.9%

Year-over-year revenue change

Profit Margin

-60.9%

How much profit the company keeps from each dollar of revenue

ROE

N/A

Return on equity — how efficiently it uses shareholder money

Analyst Target

$8.00

+152% from current price — median analyst estimate

Recommendation

STRONG_BUY

Consensus view from 5 analysts covering this stock

About TriSalus Life Sciences Inc

TriSalus Life Sciences, Inc. engages in the research, development, and commercialization of drug delivery technology platform and immuno-oncology therapeutics to improve outcomes for patients with difficult-to-treat liver and pancreatic cancers in the United States. It offers Pressure-Enabled Drug Delivery (PEDD) infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; an

https://trisaluslifesci.com

Country: United States Employees: 102 Industry: Medical Devices

Ethical Screening

Five compliance checks based on AAOIFI standards — all must pass for ethical clearance

Business Activity

PASS

Core business does not involve prohibited activities

Debt Ratio

0.0% PENDING

Debt must be below 33% of total assets

Cash Ratio

0.0% PENDING

Interest-bearing cash below 33% of assets

Receivables

0.0% PENDING

Receivables below 49% of assets

Revenue Purity

0.0% PENDING

Non-compliant revenue below 5% — any excess requires purification

Quantitative Intelligence

Statistical analysis of price behaviour, risk, and market regime — independent of fundamental data

Regime

DISTRIBUTION

Smart money appears to be selling into strength — caution

Sharpe Ratio

-0.167

Returns do not compensate for the risk — negative edge

Kelly Fraction

-0.0388

No positive edge detected — the data suggests staying out

Calmar Ratio

-0.486

Drawdown risk outweighs the returns — higher risk profile

Annual Return

-32.3%

Historical annualised return based on price data

Max Drawdown

-66.4%

Largest peak-to-trough decline — the worst it has been

HMM State

SIDEWAYS

Price consolidating — no clear directional bias

Days in State

How long the current regime has persisted — longer means more stable

Market Data

Trading characteristics and market positioning

Beta

0.56

Less volatile than the market — more defensive

52W High

$7.95

60% below the year high

52W Low

$2.20

44% above the year low

Avg Volume

366,273

Average daily shares traded — higher means easier to buy and sell

Short Ratio

3.0

Days it would take all short sellers to cover — higher means more crowded

Short % Float

N/A

Div Yield

N/A

Annual dividend as a percentage of the share price

EPS (TTM)

$-1.42

Earnings per share over the last 12 months

Financial Health

Balance sheet strength and cash generation — the foundation of long-term value

Debt/Equity

269.28

Heavy leverage — higher financial risk if revenues decline

Current Ratio

N/A

Quick Ratio

N/A

Like current ratio but excludes inventory — stricter test

Gross Margin

85.1%

Revenue left after cost of goods — higher means pricing power

Operating Margin

-94.5%

Profit from core operations before interest and tax

Free Cash Flow

$-9,303,375

Negative — the business is spending more than it generates

Revenue (TTM)

$45M

Total revenue over the last 12 months

Net Income

$-57,064,000

Loss-making — spending exceeds revenue after all costs

Analyst Coverage

Analysts

Target High

$11.00

Target Median

$8.00

Target Low

$7.00

Explore the Ethical Screener View Track Record

Data sourced from public filings and market feeds. Not financial advice. Updated: 2026-06-03

Before you go